Abstract: Objective:To analyze the clinical efficacy of levocarnitine in the treatment of ischemic cardiomyopathy(IHD) heart failure,and its effects on myocardial cell function.Methods:One hundred and thirty-six patients with ischemic cardiomyopathy heart failure were randomly divided into the observation group and control group(68 cases in each group).The control group were treated with conventional method,and the observation group were additionally treated with 3.0 g carnitine by intravenous drip once a day for 14 days on the basis of conventional treatment.The clinical efficacy,left ventricular ejection fraction(LVEF) before treatment and after 14 days of treatment,stroke volume(SV),cardiac output(CO),type B urine sodium peptide(BNP) and 6 min walking distance between two groups were compared.Results:The total effective rate after 3 months of treatment in observation group(96.6%) was significant higher than that in control group(84.8%)(P<0.01).The differences of the mortality and hospitalization rate during the 1 year following-up between two groups were statistically significant(P>0.05).The LVEF,SV,CO,BNP and 6 min walking distance in two groups after 3 months of treatment were improved(P<0.01),but the improvement in observation group were more significantly(P<0.01).The blood routine,liver and kidney functions in two groups during the treatment period were normal,the main adverse reactions included dry mouth and gastrointestinal reaction,and difference of the incidence of adverse reactions between two groups was not statistically significant(P>0.05).Conclusions:L-carnitine can obviously improve the clinical symptoms of patients with ischemic cardiomyopathy heart failure and heart function,which is high safety and worthy of clinical promotion.